Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis.
Marie MaerevoetRené-Olivier CasasnovasGuillaume CartronFranck MorschhauserCatherine ThieblemontKamal BouabdallahPierre FeugierVanessa SzablewskiStephanie BeckerHerve TillyPublished in: Cancers (2024)
Among the patients with R/R B-cell lymphoma, selinexor at a weekly dose of 40 mg with R-GDP is feasible for outpatients, with a generally acceptable safety profile.